


PRODUCT INFORMATION



WAY-169916

Item No. 35842

CAS Registry No.: 669764-18-5
Formal Name: 4-[1-(2-propen-1-yl)-7-(trifluoromethyl)-1H-indazol-3-yl]-1,3-benzenediol
MF: C₁₇H₁₃F₃N₂O₂
FW: 334.3
Purity: ≥98%
UV/Vis.: λ_{max}: 235, 336 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

WAY-169916 is supplied as a solid. A stock solution may be made by dissolving the WAY-169916 in the solvent of choice, which should be purged with an inert gas. WAY-169916 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of WAY-169916 in DMSO is approximately 15 mg/ml and approximately 10 mg/ml in ethanol and DMF.

Description

WAY-169916 is a pathway-selective estrogen receptor (ER) ligand.¹ It binds to human ERα and ERβ (IC₅₀ = 3 nM for both) and inhibits IL-1β-induced NF-κB reporter activity in HAECT-1 cells expressing human ERα (IC₅₀ = 93 nM), but not cells lacking ER expression, when used at concentrations up to 10 μM. WAY-169916 (1 μM) reduces increases in creatine kinase (CK) activity induced by the ER agonist 17β-estradiol (Item No. 10006315) in HAECT-1 cells. *In vivo*, WAY-169916 (10 mg/kg per day) reduces high-fat diet-induced hepatic NF-κB activity and inflammatory gene expression without increasing uterine weight in ovariectomized rats. It inhibits chronic diarrhea, as well as intestinal ulceration and inflammatory cell infiltration, in an HLA-B27 transgenic rat model of inflammatory bowel disease (IBD). WAY-169916 (1 mg/kg) reduces infarct size in an ovariectomized rabbit model of coronary artery occlusion-induced ischemia and reperfusion injury.²

References

1. Chadwick, C.C., Chippari, S., Matelan, E., *et al.* Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. *Proc. Natl. Acad. Sci. U.S.A.* **102**(7), 2543-2548 (2005).
2. Booth, E.A., Marchesi, M., Knittel, A.K., *et al.* The pathway-selective estrogen receptor ligand WAY-169916 reduces infarct size after myocardial ischemia and reperfusion by an estrogen receptor dependent mechanism. *J. Cardiovasc. Pharmacol.* **49**(6), 401-407 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM